ArticleArchives of toxicology2026
Dexamethasone alters the cornea transcriptome to confer protection against ocular sulfur mustard exposure via regulating NFκB and TGFβ signaling in an in vivo rabbit model.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Ocular exposure to sulfur mustard (SM), infamously called "King of Battle Gases", may occur during warfare, terrorist activities, or accidentally from improperly discarded munitions/stockpiles. Eyes, particularly corneas, are exceptionally vulnerable to SM toxicity. Notably, SM is a potent genotoxicant that causes damage to proteins, lipids, and nucleic acids. Currently, no approved therapeutics are available for ocular SM injuries. We developed a dexamethasone (DEX; 0.1%) treatment plan (application initiation 2 h post-exposure and every 8 h thereafter for 28 days) that effectively countered mustard vesicant-induced corneal injuries. However, the mechanistic aspects of SM toxicity and DEX efficacy remain elusive. Thus, rRNA-depletion RNA sequencing was performed on day 14 and day 28 post-SM exposure (neat) to assess the progression of SM toxicity and DEX efficacy at the transcriptome level in corneas (in vivo rabbit studies) from control, SM-exposed, and DEX-treated tissues. Transcripts significantly differentially expressed between all three groups (omnibus FDR < 0.01) were further analyzed based on pairwise differences between treatment groups. Further, network analyses and functional enrichment studies were performed to decipher SM toxicity and DEX efficacy-associated effects as a function of time. Twenty-day treatment was found to be more effective than 4-day DEX treatment. Main mechanisms associated with DEX efficacy included NFκB and TGFβ signaling. The most prominent functional aspects associated with SM toxicity and DEX efficacy were preservation of the corneal structural integrity via regulating collagen networks and angiogenesis. These novel outcomes provide in-depth mechanistic insights into DEX efficacy for treating SM-induced corneal injuries.
Indexed as
Identifiers
41026206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.